Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perillyl alcohol intranasal - NEONC Technologies

Next Previous
Drug Profile

Perillyl alcohol intranasal - NEONC Technologies

Alternative Names: NEO 100; Perillyl-alcohol-intranasal-NEONC-Technologies; POH

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NEONC Technologies
  • Developer National Cancer Institute (USA); NEONC Technologies
  • Class Monoterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Meningioma
  • Phase I/II Glioma
  • No development reported Glioblastoma
  • Discontinued Cancer

Most Recent Events

  • 12 Apr 2024 Neonc Technologies plans a phase I trial for Brain cancer (In Adolescents, In children, Recurrent) (Intranasal), in May 2024 (NCT06357377)
  • 01 Jul 2022 Phase-II clinical trials in Meningioma (Recurrent, Metastatic disease, Second-line therapy or greater) in USA (Intranasal) (NCT05023018)
  • 27 Sep 2021 No development reported - Phase-I/II for Glioblastoma (Recurrent) in Brazil (Intranasal) (NEONC Technologies' pipeline, September 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top